Association of Soluble Receptor for Advanced Glycation End Products Levels with Hypertensive Albuminuria
Objective: Soluble receptor for advanced glycation end products (sRAGE) levels have been
found to be decreased in chronic inflammatory diseases including atherosclerosis, hypertension and
renal failure. This study evaluated the relationship between sRAGE concentrations and urinary albumin
excretion in patients with essential hypertension. Methods: A total of 200 consecutive patients
with essential hypertension were enrolled and were divided into 3 groups. Results: Plasma sRAGE
levels were significantly lower in hypertensive patients with micro- or macroalbuminuria compared with those in hypertensive
patients with normoalbuminuria, and the values in the macroalbuminuria group were even lower than in the microalbuminuria
group (128.6±24.2, 244.6±37.6313.6±30.7 pg/ml respectively). In addition, plasma sRAGE level was
an independent determinant of log urinary albumin excretion in patients with essential hypertension (β=0.267, P<0.05).
Conclusions: sRAGE may play a role in the pathogenic processes that link albuminuria, chronic inflammation and oxidative
stress in hypertensive patients.
Keywords: Albuminuria, hypertension, receptor for advanced glycation end products.
Rights & PermissionsPrintExport